Impact of rituximab on relapse rate and disability in neuromyelitis optica

Background: Neuromyelitis optica (NMO) is a severe demyelinating disease often leading to serious disability. Accumulating evidence now implicates humoral mechanisms in its pathogenesis. In the absence of an approved therapy, anti-inflammatory/immunosuppressant drugs have been used empirically for m...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Multiple sclerosis 2011-10, Vol.17 (10), p.1225-1230
Hauptverfasser:	Bedi, Gurdesh S, Brown, Andrew D, Delgado, Sylvia R, Usmani, Nida, Lam, Byron L, Sheremata, William A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal, Murine-Derived - therapeutic use Biological and medical sciences Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Disability Evaluation Female Humans Immunologic Factors - therapeutic use Longitudinal Studies Male Medical sciences Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Neurology Neuromyelitis Optica - complications Neuromyelitis Optica - prevention & control Retrospective Studies Rituximab Secondary Prevention Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!